You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 6,365,581

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,365,581

Title:	Use of mometasone furoate for treating airway passage and lung diseases
Abstract:	The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
Inventor(s):	Sequeira; Joel A. (Scotch Plains, NJ), Cuss; Francis M. (Basking Ridge, NJ), Nolop; Keith B. (Millburn, NJ), Chaudry; Imtiaz A. (North Caldwell, NJ), Nagabhushan; Nagamani (Parsippany, NJ), Patrick; James E. (Belle Meade, NJ), Cayen; Mitchell (Bedminster, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	09/535,208
Patent Claims:	1. A method of treating a corticosteroid-responsive disease of the lower airway passages or lungs in patients afflicted with said disease, which comprises administering to the surfaces of said passages or lungs of said patients aerosolized particles of mometasone furoate in an amount effective for treating said disease and resulting in negligible systemic effects. 2. The method of claim 1 wherein the disease comprises an allergic or inflammatory disease of the lower airway passages and/or lungs. 3. The method of claim 1 wherein the disease comprises asthma. 4. The method of claim 1, wherein the disease comprises chronic obstructive pulmonary disease. 5. The method of claim 1 wherein the disease comprises a granulomatous disease. 6. The method of claim 1, wherein the disease comprises a nonmalignant proliferative or inflammatory disease. 7. The method of claim 1, wherein the disease comprises idiopathic pulmonary fibrosis. 8. The method of claim 1, wherein the disease comprises bronchopulmonary dysphasia. 9. The method of claim 1, wherein the disease comprises hypersensitivity pueumonitis. 10. The method of claim 1, wherein the daily amount of mometasone furoate administered is about 10 to about 2000 micrograms. 11. The method of claim 1, wherein the daily amount of mometasone furoate administered is about 50 to about 1000 micrograms. 12. The method of claim 1, wherein the mometasone furoate is administered at least once daily. 13. The method of claim 1, wherein the mometasone furoate is administered once daily. 14. The method of claim 1, wherein the mometasone furoate is administered twice daily. 15. The method of claim 1, wherein the mometasone furoate is administered by oral inhalation. 16. The method of claim 1, wherein the mometasone furoate is administered from a pressurized aerosol metered dose inhaler. 17. The method of claim 1, wherein the mometasone furoate is administered from a dry power inhaler. 18. A method of treating a corticosteroid-responsive allergic or inflammatory disease of the lower airway passages or lungs, which comprises administering as initial or maintenance therapy to the surfaces of said passages or lungs, once or twice daily, an amount of aerosolized particles of mometasone furoate effective for treating said disease and resulting in negligible systemic activity. 19. The method of claim 18, wherein the disease comprises at least one disorder selected from the group consisting of asthma, chronic obstructive pulmonary disease, a granulomatous disease, a non-malignant proliferative or inflammatory disease, idiopathic pulmonary fibrosis, bronchopulmonary dysphasia and hypersensitivity pneumonitis. 20. The method of claim 18, wherein the daily amount of mometasone furoate administered is about 10 to about 2000 micrograms. 21. The method of claim 18, wherein the daily amount of mometasone furoate administered is about 50 to about 1000 micrograms. 22. The method of claim 18, wherein the mometasone furoate is administered once daily. 23. The method of claim 18, wherein the mometasone furoate is administered by oral inhalation. 24. The method of claim 18, wherein the mometasone furoate is administered from a pressurized aerosol metered dose inhaler. 25. The method of claim 18, wherein the mometasone furoate is administered from a dry powder inhaler.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.